Canada Markets open in 6 hrs 29 mins

Adamas Pharmaceuticals, Inc. (ADMS)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
8.17-0.03 (-0.37%)
At close: 04:00PM EST
Full screen
Loading interactive chart...
  • GlobeNewswire

    Supernus Pharmaceuticals Completes Acquisition of Adamas Pharmaceuticals

    Acquisition strengthens Parkinson’s disease portfolio and diversifies revenue and cash flowROCKVILLE, Md., Nov. 24, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) today announced that it has successfully completed its previously announced acquisition of Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS). “Adamas fits squarely within our corporate development strategy, adding a late-stage commercial product with significant revenue,” said Jack Khattar, President and CEO of Supern

  • GlobeNewswire

    Supernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Adamas Pharmaceuticals Tender Offer

    ROCKVILLE, Md., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) today announced that the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) with respect to Supernus’ proposed acquisition of Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS) expired at 11:59 p.m. on November 22, 2021. On October 21, 2021, Supernus and Adamas filed the Premerger Notification and Report Forms required under the HSR Act with the Federal Trade Com

  • ACCESSWIRE

    STOCKHOLDER ALERT: Monteverde & Associates Continues to Investigate the Following Merger

    NEW YORK, NY / ACCESSWIRE / November 12, 2021 /Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018-2020 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating: * Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) relating to its proposed acquisition by Supernus Pharmaceuticals, Inc.